Protagenic Therapeutics, Inc.new - *W EXP 04/26/202 (PTIXW)

CUSIP: 74365N111

Q1 2023 13F Holders as of 31 Mar 2023

Share change
+16,547
SEC-reported price per share
$0.02
Indexed holders
3
Value change
+$397
Number of buys
1
Number of sells
1

Security key

74365N111

Report period

Q1 2023

Indexed institutions

3

Top holders

3

Ownership snapshot

Top reported holders of PTIXW - Protagenic Therapeutics, Inc.new - *W EXP 04/26/202 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
0/15
Latest evidence
31 Dec 2022
13F Highest disclosed value: $94,523 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

VANGUARD GROUP INC has the largest disclosed position value at $94.5K.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VANGUARD GROUP INC's linked filing trail.
Disclosed position value Top 5
VANGUARD GROUP INC $94.5K
GEODE CAPITAL MANAGEMENT, LLC $43K
FNY Investment Advisers, LLC $31K
STATE STREET CORP $23.1K
Warberg Asset Management LLC $15.3K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$94,523
236,309 shares
— 31 Dec 2022
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$43,000
103,595 shares
— 31 Dec 2022
FNY Investment Advisers, LLC
13F
Company
13F
—
denominator unverified
$31,000
75,000 shares
— 31 Dec 2022
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$23,093
55,246 shares
— 31 Dec 2022
Warberg Asset Management LLC
13F
Company
13F
—
mixed-class rows
$15,265
197,196 shares
mixed-class rows
— 31 Dec 2022
CITADEL ADVISORS LLC
13F
Company
13F
—
denominator unverified
$9,815
23,482 shares
— 31 Dec 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
3
Shares
217,707
Indexed holders
3
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2023 vs Q4 2022 Across Filers

Q4 2022 indexed holders
2
Q1 2023 indexed holders
3
Indexed holder difference
1
Investor Q4 2022 Shares Q1 2023 Shares Share Diff Share Chg % Q4 2022 value Q1 2023 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .